FDA panel endorses Pfizer vaccines for 5-11 year olds

FDA panel endorses Pfizer vaccines for 5-11 year olds
By Tina Reed

Members of the Food and Drug Administration's vaccine expert panel on Tuesday endorsed a two-dose series of Pfizer-BioNTech's COVID-19 vaccine for children ages 5- to 11-years-old. The final vote was 17 members in favor, with one member abstaining.

Why it matters: While not binding, the decision is a long-awaited step toward getting COVID vaccines in the arms of some of the youngest Americans potentially in time to get many fully vaccinated in advance of the holiday season.

By the numbers: Pfizer and BioNTech said their COVID-19 vaccine was more than 90% effective at protecting children between the ages of 5 and 11 from symptomatic infections from the virus, according to a study posted online by the FDA last week.

Be smart: The advisory committee continuously referred their discussion back to the potential risk-benefit analysis for vaccinating kids, particularly considering the small increased risk of heart inflammation called myocarditis.

  • That was particularly the case due to declining COVID-19 case rates nationwide in recent weeks, as well as potentially at many as 40% of children who may have already some immunity due to a previous infection.
  • Officials said they believe the modeling may overestimate the risks for myocarditis, but several panel members pointed out the lingering questions about the actual rate.

But, but, but: "We've been assuming we're on the descending slope of the curve previously and been caught flat-footed as the rates again went up so thinking this is going to be the end of the wave permanently may be a little overly optimistic," said Arnold Monto, chairman of the advisory panel.

Several advisory board members indicated they were concerned about approving the vaccine for all children in the age group because potential mandates could come down based on their vote.

  • 'This is a much tougher one than we expected going into this," said advisory board member Eric Rubin, an adjunct professor of immunology and infectious diseases at the Harvard T. H. Chan School of Public Health, of Harvard Medical School.
  • Others raised questions about whether a one-dose regimen would be more appropriate for kids.

But, many of them said they ultimately wanted to make the vaccine available to kids available at highest risk from COVID such as those with underlying medical conditions. Many of those kids have been forced to stay home which comes with its own risks to their well-being.

  • The advisory board said they were also concerned about preventing the risks of long COVID in children.
  • "If I were a parent of a child in this age group, I would want to have the choice. We can’t have the choice unless the vaccine is available,” said A. Oveta Fuller, an African Studies Center International Institute associate professor of microbiology and immunology at the University of Michigan Medical School.

What we're watching: FDA acting commissioner Janet Woodcock will ultimately make the call on approval. If it does get the OK, it will head to the CDC for consideration next week.

  • The White House said it secured enough vaccine supply to equip more than 25,000 pediatric and primary care offices, hundreds of school and community health clinics, and tens of thousands of pharmacies to administer the shots.




October 26, 2021 at 11:20PM
via Axios https://ift.tt/3vQDuhM

Comments

Post a Comment

Popular posts from this blog

Five Burning Questions: Nardo Wick’s Star-Studded ‘Who Want Smoke?’ Debuts in the Top 20

In what’s been a relatively slow year for breakout hits from new artists, we haven’t seen a lot of first-timers climbing into the top 20 of the Hot 100 — but fewer still who debut there as a lead artist. That’s what 19-year-old Jacksonville rapper Nardo Wick does this week with his breakout single, “Who Want Smoke??” Of course, he doesn’t appear alone on his No. 17-bowing hit: He’s assisted by a trio of more established hitmakers in 21 Savage, Lil Durk and G Herbo, all of whom appear on the song’s now-viral remix. What’s responsible for the song’s big debut? And who steals the show on the remix?  Billboard staffers discuss these questions and more below. 1. A top 20 Hot 100 debut is obviously a tremendous showing for an artist without much Billboard history to their name. Aside from the sheer star power of the guest list, what about “Who Want Smoke??” do you think is most responsible for its resounding debut? Josh Glicksman : The star-studded guest list definitely has ...
Read more

Olivia Rodrigo Responds to ‘Sour’ Songwriting Criticism: ‘Nothing in Music Is Ever New’

In a new interview, Olivia Rodrigo addresses criticism about the originality of her Billboard 200 -topping debut album Sour  after she retroactively added songwriting credits to a handful of her hit songs. “I think it’s disappointing to see people take things out of context and discredit any young woman’s work,” the 18-year-old told Teen Vogue . “But at the end of the day I’m just really proud and happy to say that my job is being a songwriter. … All music is inspired by each other. Obviously, I write all of my lyrics from my heart and my life first. I came up with the lyrics and the melody for ‘good 4 u’ one morning in the shower.” In August, months after Sour ’s release, Rodrigo added  Paramore ’s  Hayley Williams  and  Joshua Farro  to the  songwriting credits  for the Billboard Hot 100 -topping “good 4 u” because of its similarities to the band’s 2008 top 40 hit “Misery Business.” The singer also credited her idol Taylor Swift , as wel...
Read more